The Motley Fool
01 Jul 2026, 03:38 UTC · 3h ago
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
01 Jul 2026, 03:38 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
UroGen Pharma's Zusduri sales increased significantly to $29.2 million in Q1 2026 from $15.8 million in Q4 2025. — Rapid revenue growth for a core product is a strong positive indicator of commercial traction and future cash flow.
+0.60UroGen Pharma's net losses narrowed to $23.6 million in Q1 2026 compared to a loss of $43.8 million in the same period previous year. — A shrinking loss profile suggests the company is moving toward profitability and reducing its cash burn.
+0.40UroGen's Jelmyto product sales are projected to grow to a range of $97 million to $101 million from $94 million in 2025. — Steady growth in an existing product line provides a reliable baseline for valuation.
+0.30Continue reading
6 related stories
Search tags
The company's UGN-103 candidate produced study results in line with the successful Zusduri treatment. — Positive clinical data for a new candidate suggests a potential new revenue stream and expanded market reach.
+0.30Chief Medical Officer Mark Schoenberg sold 10,000 shares of common stock on June 22, 2026. — Insider selling is generally viewed as a slight negative, though the scale here is noted as small relative to total holdings.
-0.10Which stocks this story touches
The company reports soaring sales for Zusduri, shrinking losses, and positive clinical results for UGN-103.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
3h ago
